ZymoGenetics said an early clinical trial of an anti-viral compound is showing "meaningful reduction" in Hepatitis C virus in relapsed patients.

Share story

ZymoGenetics said an early clinical trial of an anti-viral compound is showing “meaningful reduction” in hepatitis C virus in relapsed patients.

The Seattle biotechnology company said it will accelerate its timeline for further studies of the compound, PEG-Interferon lambda, in combination with an existing drug, ribavarin.

“PEG-Interferon lambda has become one of our company’s key assets,” said ZymoGenetics chief medical officer Nicole Onetto. “Based on these early results, we’re encouraged by the potential for PEG-Interferon lambda to become an effective treatment with improved tolerability for treating patients with Hepatitis C.”

The interim results were disclosed late Monday afternoon at a conference in San Francisco, said spokeswoman Susan Specht.

ZymoGenetics shares jumped 17 percent to $3.75 before that report. The stock is down from a 52-week high of $15.23.